Annovis Bio, Inc.

NYSE:ANVS

Biotechnology

Healthcare
$1.21 +0.00%

+$0.00 today

Market cap
$51.64M
Beta
1.24
P/E (TTM)
-1.1
EPS (TTM)
-$1.47
52W Low $1.54High $5.50

Volume 1.35M

Average 1.08M

Returns on capital

Annovis Bio, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-171.2%

avg 14.0%

ROIC

-170.2%

avg -63.7%

ROA

-136.9%

avg -301.4%

Analysis

ROA is currently the strongest return metric at -136.9% versus its period average of -301.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Maria L. Maccecchini

Founder, Acting CFO, CEO, President & Executive DirectorUSD 808K75——

Hilda Maibach

Senior Vice President of Statistics————

Cheng Fang

Chief Scientific Officer————

Blake Jensen

Head of Quality————

Eve Damiano

Senior Vice President of Regulatory Operations————

Compensation is shown in the reported currency; data updated Sep 26, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

16

$2.23M

Sells

0

$0.00

Net Transaction Value

+$2.23M

Net buying

Most Active

Hoffman Michael B

16 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
May 20, 26

Hoffman Michael B

Direct

Buy$104.4K
May 20, 26

Hoffman Michael B

Direct

Buy$33.9K
May 20, 26

Hoffman Michael B

Direct

Buy$4.5K
Apr 2, 26

Hoffman Michael B

Direct

Buy$1.5M
Dec 8, 25

Hoffman Michael B

Direct

Buy$63.6K
Dec 8, 25

Hoffman Michael B

Direct

Buy$130.2K
Nov 24, 25

Hoffman Michael B

Direct

Buy$116.6K
Nov 24, 25

Hoffman Michael B

Direct

Buy$1.7K
Nov 24, 25

Hoffman Michael B

Direct

Buy$35.4K
Nov 24, 25

Hoffman Michael B

Direct

Buy$6.1K

1–10 of 16

Summary

Insiders reported 16 buys worth $2.23M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $2.23M. Hoffman Michael B was the most active insider with 16 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A —
RevenueN/AN/AN/A
N/A —
Net IncomeN/AN/AN/A
N/A —
EBITN/AN/AN/A
N/A —

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Annovis Bio, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ANVS's management, answered from reported figures.

Who manages ANVS?

Annovis Bio, Inc. (ANVS) lists 5 active executives. The top listed executive is Hilda Maibach, Senior Vice President of Statistics.

Are ANVS insiders buying or selling?

Recent insider activity shows net buying of $35.39M.